T3 Pharmaceuticals Closes Second Financing Round

September 27, 2019

T3 Pharmaceuticals, a Swiss company that focuses on immuno-oncology, has announced the closing of its second round of investment financing in which it raised more than CHF 12 million (US$12.1 million).

T3 Pharmaceuticals, a Swiss company that focuses on immuno-oncology, has announced the closing of its second round of investment financing in which it raised more than CHF 12 million (US$12.1 million), in a Sep. 26, 2019 press release.

The investment in this latest financing round was made by existing investors in addition to Boehringer Ingelheim Venture Fund and Reference Capital SA. Further to the additional financing, the company has revealed a new appointment to its development team-Claire Barton, who will be the company’s chief medical officer. 

“We are very pleased to be joined by two experienced and specialized investors, the Boehringer Ingelheim Venture Fund and Reference Capital SA. This is optimal for completing preclinical work, and for planning and conducting the clinical trials ahead of us,” said Simon Ittig, CEO of T3, in the press release. “The support of these investors validates our work and indicates that we are on the right track. This strong setup allows us to keep focusing on our core business. Special thanks are due to our existing investors who have supported us since inception.”

Source: T3 Pharmaceuticals